Literature DB >> 2673757

Hazards of inference: the active control investigation.

P D Leber1.   

Abstract

A finding of no significant difference in seizure incidence and/or severity among groups of epileptic patients prospectively randomized to treatment with either a standard or experimental antiepileptic drug is often advanced as compelling proof of the latter's anticonvulsant efficacy. Regrettably, the finding of no difference does not, on its own at least, support such a conclusion. A finding of no difference between treatments has numerous explanations that have nothing whatsoever to do with the pharmacological actions of the experimental drug. To be clear, it is possible to argue that a pharmacological effect is the most plausible explanation for a finding of no difference in an active control study, but this argument is only supportable if it is based on additional information gathered from sources external to the study. In most circumstances, the essential external evidence is not available, and the interpretation of the null difference as a positive result turns entirely upon the truth or falsity of the sanguine assumptions made. There is a risk in inferring efficacy from the seemingly consistent results of a series of active control studies that fail to find differences. Despite the long-recognized deficiencies in the active control study design, it remains popular.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2673757     DOI: 10.1111/j.1528-1157.1989.tb05816.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  13 in total

1.  The necessity and the value of placebo.

Authors:  Ernst A Singer
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

Review 2.  Active control equivalence trials: some methodological aspects.

Authors:  U Ferner; N Neumann
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  FDA: evidentiary standards for drug development and approval.

Authors:  Russell Katz
Journal:  NeuroRx       Date:  2004-07

4.  Comparative monotherapy trials and the clinical treatment of epilepsy.

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2007 Sep-Oct       Impact factor: 7.500

5.  Integrating statistical and clinical research elements in intervention-related grant applications: summary from an NIMH workshop.

Authors:  Joel T Sherrill; David I Sommers; Andrew A Nierenberg; Andrew C Leon; Stephan Arndt; Karen Bandeen-Roche; Joel Greenhouse; Donald Guthrie; Sharon-Lise Normand; Katharine A Phillips; M Katherine Shear; Robert Woolson
Journal:  Acad Psychiatry       Date:  2009 May-Jun

Review 6.  Drug treatment of epilepsy in the 1990s. Achievements and new developments.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 7.  New avenues for anti-epileptic drug discovery and development.

Authors:  Wolfgang Löscher; Henrik Klitgaard; Roy E Twyman; Dieter Schmidt
Journal:  Nat Rev Drug Discov       Date:  2013-09-20       Impact factor: 84.694

8.  Clinical and statistical issues in therapeutic equivalence trials.

Authors:  E Garbe; J Röhmel; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 9.  Evaluation of drug treatment outcome in epilepsy: a clinical perspective.

Authors:  E Perucca
Journal:  Pharm World Sci       Date:  1997-10

Review 10.  Designing clinical trials to assess antiepileptic drugs as monotherapy : difficulties and solutions.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.